Age At Onset
Introduction
Age at onset refers to the specific age at which the first symptoms or signs of a disease or condition become apparent. This trait is a quantitative phenotype, meaning it can be measured numerically, and its variability among individuals is often influenced by a complex interplay of genetic and environmental factors. Understanding age at onset is crucial in the study of various complex human diseases, including neurodegenerative disorders like Parkinson disease (PD) and Alzheimer disease, as well as psychiatric conditions such as attention deficit hyperactivity disorder (ADHD) and bipolar disorder. [1]
Biological Basis
The timing of disease manifestation is often highly heritable, with genetic factors playing a significant role in determining when symptoms first appear
The challenge of reaching stringent genome-wide significance thresholds (e.g., p < 5 × 10^-8) is a recurring issue, especially when multiple genetic models (additive, dominant, recessive) are tested, which increases the burden of multiple comparisons. Furthermore, observed effect sizes may be inflated due to the "Winner's Curse," meaning initial findings might overstate the true genetic effect and require confirmation through independent replication studies. Differences in age distributions or other characteristics across study populations can also introduce heterogeneity, making consistent replication difficult and potentially limiting the reliability of combined findings. [1]
Phenotype Definition and Population Generalizability
The precise definition and measurement of age at onset can introduce variability and potential error, impacting the statistical power to detect associations. For instance, excluding cohorts with limited variability in age at onset, such as those restricted to older ages, can reduce the overall range of the phenotype being studied, limiting the ability to detect genetic effects that influence earlier or later onset. Moreover, uncertainty in the recorded age at onset can lead to the exclusion of cases during quality control, further reducing sample size and potentially introducing selection bias. [1]
Many genome-wide association studies (GWAS) are primarily conducted in populations of European descent, which limits the generalizability of findings to other ancestral groups. While efforts are made to adjust for population stratification using principal components, the exclusion of non-Caucasian admixed individuals or reliance on reference panels like HapMap CEU for imputation means that variants or genetic architectures specific to other populations may be missed or inaccurately represented. This can hinder the comprehensive understanding of genetic influences on age at onset across the diverse human population. [2]
Unaccounted Genetic and Environmental Influences
Age at onset is a complex trait influenced by a myriad of environmental factors and their interactions with genetic predispositions. Factors like socio-economic status, lifestyle choices (e.g., use of nicotine replacement therapy), or other medical conditions can confound genetic associations if not adequately measured and accounted for in analyses. The impact of known genetic confounders, such as APOE genotype in Alzheimer's disease, also necessitates careful adjustment, as differential allele frequencies across populations or disease subgroups can significantly influence observed associations and genomic control. [3]
Despite identifying significant genetic loci, GWAS often explain only a fraction of the heritability for complex traits, a phenomenon known as "missing heritability." This suggests that many genetic variants with small effects, rare variants, or complex gene-gene and gene-environment interactions may remain undetected by current study designs and statistical methods. Future research needs to explore these intricate interactions and the cumulative effect of many small genetic contributions to fully unravel the genetic underpinnings of age at onset. [3]
Variants
Genetic variations play a crucial role in influencing a wide spectrum of human traits, including the age at which certain health conditions manifest or the overall trajectory of aging. Many genome-wide association studies (GWAS) have been conducted to identify single nucleotide polymorphisms (SNPs) and genes that correlate with age-related phenotypes, longevity, and the age at onset of various diseases. [4] These investigations highlight the complex genetic architecture underlying the timing and progression of aging-related processes, aiming to uncover genetic modifiers that could serve as therapeutic targets to delay disease onset. [1]
Several genes involved in fundamental cellular processes, structural integrity, and neurological function have variants implicated in age-related traits. For example, TSPAN10 (Tetraspanin 10) encodes a cell surface protein that organizes molecular complexes crucial for cell adhesion, migration, and signaling, processes vital for maintaining tissue health throughout life. LAMA2 (Laminin Alpha 2) is essential for the basal lamina, a key component of the extracellular matrix providing structural support to tissues like muscle and nerve; variations here can impact age-related decline in physical function. KCNQ5 (Potassium Voltage-Gated Channel Subfamily Q Member 5) encodes an ion channel that regulates neuronal excitability and smooth muscle activity, with implications for age-related neurological and cardiovascular health. Similarly, LRRC4C (Leucine Rich Repeat Containing 4C) contributes to neuronal development and synapse formation, suggesting its variants could affect age-related cognitive changes. Understanding these genetic influences helps elucidate the broad genetic landscape that shapes human aging and disease susceptibility. [1]
Genes associated with barrier function and immune responses also contribute to age-related phenotypes. CCDST and FLG (Filaggrin) are critical for maintaining the skin barrier, and variants in FLG are well-known for their association with atopic dermatitis and other inflammatory skin conditions, which can impact quality of life and susceptibility to other conditions as individuals age. GSDMB (Gasdermin B) is involved in programmed cell death, specifically pyroptosis, and plays a role in inflammatory responses, with variations linked to asthma and other inflammatory disorders. Chronic inflammation, often referred to as "inflammaging," is a significant contributor to numerous age-related diseases, making variants in these genes relevant to the onset and severity of age-related inflammatory conditions. [4] Genetic studies frequently explore such connections to identify how specific genetic profiles influence disease presentation and progression over time. [1]
Other variants influence more specialized functions, from intercellular communication to sensory processing and gene regulation. The intergenic region involving LINC02252 and GJD2 (Gap Junction Delta 2) highlights the importance of gap junctions in cell-to-cell communication, which is vital for tissue homeostasis and can be compromised in age-related diseases. RDH5 (Retinol Dehydrogenase 5) is crucial for the visual cycle in the retina; variants like rs3138141 and rs3138142 are associated with retinal dystrophies that can lead to progressive vision loss, directly affecting age-related sensory health. RBFOX1 (RNA Binding Fox-1 Homolog 1) is an RNA binding protein that regulates alternative splicing, particularly in the nervous system, meaning its variants (rs10500355, rs17648524, rs58514548) could impact neuronal health and cognitive function with age. Finally, the TOX-DT - RNA5SP267 region, including rs72621438, may influence gene expression through regulatory elements or pseudogenes, potentially affecting the onset of complex age-related conditions through subtle changes in cellular pathways. These diverse genetic factors collectively contribute to the individual variability observed in the age at onset of diseases like Alzheimer's and Parkinson's, underscoring the broad impact of genetic modifiers on healthy aging . [1], [5]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7405453 | TSPAN10 | cortical thickness brain connectivity attribute macula attribute brain attribute eye disease |
| rs12193446 | LAMA2 | refractive error, self reported educational attainment axial length measurement Hypermetropia Myopia Hypermetropia, Myopia |
| rs61816761 | CCDST, FLG | asthma childhood onset asthma allergic disease sunburn vitamin D amount |
| rs524952 rs589135 |
LINC02252 - GJD2 | refractive error, self reported educational attainment Abnormality of refraction Myopia Hypermetropia, Myopia eye disease |
| rs4795399 rs4795400 rs921650 |
GSDMB | asthma childhood onset asthma age at onset age of onset of childhood onset asthma |
| rs7744813 | KCNQ5 | refractive error, self reported educational attainment Abnormality of refraction Myopia eye disease cataract |
| rs11602008 | LRRC4C | Myopia Hypermetropia, Myopia refractive error age at onset Hypermetropia |
| rs3138141 rs3138142 |
RDH5 | atrophic macular degeneration, age-related macular degeneration, wet macular degeneration Myopia age-related macular degeneration, COVID-19 age at onset retinopathy |
| rs10500355 rs17648524 rs58514548 |
RBFOX1 | Abnormality of refraction Myopia cataract age at onset |
| rs72621438 | TOX-DT - RNA5SP267 | Myopia refractive error retinal vasculature measurement age at onset Abnormality of refraction |
Defining Age at Onset: Conceptual Frameworks and Key Terminology
Age at onset is a critical temporal characteristic used across various medical and biological contexts, representing the age at which a particular trait, symptom, or condition first manifests. Conceptually, it often functions as a continuous phenotype, allowing for quantitative analysis, such as through linear regression models in genetic studies. [6] This precise temporal marker is vital for understanding disease etiology, progression, and genetic influences, as evidenced by studies supporting the importance of age-related aspects in interpreting genome-wide association study (GWAS) signals. [7] Key terms like "age at menarche" for the onset of the first menstrual period, "age at onset of ADHD" for the first appearance of ADHD symptoms, and "young-onset hypertension" specify the particular condition being timed, while "early-onset extreme obesity" highlights both the timing and severity of a trait. [8]
The nomenclature surrounding age at onset reflects its diverse applications. "Puberty," for instance, is a complex, multistaged process of growth and sexual maturity over a 2- to 3-year period, with "age at menarche" serving as a distinct and well-recalled indicator of its timing in girls. [8] For conditions like attention deficit hyperactivity disorder (ADHD), the "age at onset" may refer specifically to the parent-reported age when symptoms were first observed, which might precede an official diagnosis based on specific diagnostic criteria. [9] This distinction underscores that the reported age at onset can sometimes reflect symptom emergence rather than a formal clinical diagnosis, yet it remains a genetically relevant phenotype. [9]
Operational Definitions and Measurement Criteria
Operational definitions for age at onset vary significantly by condition, employing specific measurement criteria and thresholds to ensure precision. For early-onset extreme obesity in children and adolescents, the trait is defined using Body Mass Index (BMI) percentile criteria from large population-based samples. "Obesity" is typically defined as a BMI at or above the 97th percentile, while "overweight" is at or above the 90th percentile, with cases of "extreme obesity" often exceeding the 99th percentile. [7] Measurement of BMI in children and adolescents involves a normalized version, the BMI standard deviation score (BMI-SDS), derived using Cole's least mean square method, which standardizes BMI relative to age and gender. [7]
Similarly, specific clinical criteria define "young-onset hypertension (YOH)," requiring a systolic blood pressure (SBP) of at least 140 mmHg and/or a diastolic blood pressure (DBP) of at least 90 mmHg over a two-month period, or controlled SBP/DBP values if on anti-hypertensive medication, with an initial diagnosis between 20 and 51 years of age. [10] This definition also includes rigorous exclusion criteria, such as ruling out secondary causes of hypertension and ensuring fasting glucose levels below 126 mg/dl, along with a BMI below 35 kg/m2. [10] For "age at menarche," the measurement relies on participant recall, with studies often including responses falling within the normal physiological range of 9 to 17 years. [11]
Classification Systems and Clinical Significance
The concept of age at onset is integral to various classification systems, allowing for the categorization of conditions and the identification of distinct subtypes. The distinction between "early-onset" and later-onset forms of a disease is a common categorical approach, as seen in "early-onset extreme obesity" and "young-onset hypertension". [7] These classifications can have significant clinical implications, often correlating with different genetic architectures, disease severities, or prognoses. For instance, the use of extreme percentile cut-offs (e.g., BMI >=97th or >=99th percentile) for defining "extreme obesity" in children highlights a severity gradation within the broader category of obesity. [7]
While some conditions like obesity and hypertension use specific thresholds to define categorical "early-onset" forms, age at onset can also be approached dimensionally. In genetic association studies for conditions such as Parkinson disease and bipolar disorder, age at onset is frequently treated as a continuous variable, allowing researchers to model its association with genetic variants using linear regression. [1] This dimensional approach can reveal subtle genetic influences across the spectrum of onset ages, supporting the idea that the impact of certain genetic loci may be limited to specific age groups, underscoring the importance of age-related considerations in genetic research. [7]
Biological Background
The age at which symptoms of a disease, such as Parkinson's disease (PD), first appear is a complex and highly heritable quantitative trait, significantly influenced by a combination of genetic, cellular, and systemic biological factors. [1] Understanding the biological underpinnings of 'age at onset' provides critical insights into pathogenic mechanisms, disease penetrance, and potential therapeutic targets aimed at delaying symptom manifestation. [1]
Genetic Modifiers of Disease Onset
Genetic factors play a substantial role in determining the age of disease onset, with specific genes and their variants influencing when symptoms first emerge. For instance, mutations in genes like PARK1 are associated with a younger onset of PD compared to typical idiopathic forms. [1] Similarly, recessive mutations in PARK2 commonly lead to very early onset, often before age 40, and even heterozygous PARK2 mutations can result in an earlier onset, typically in the early to mid-sixth decade. [1] In contrast, LRRK2 mutations exhibit an onset distribution similar to idiopathic PD, characterized by clear age-dependent penetrance, where the likelihood of developing the disease increases with advancing age. [1]
Genome-wide association studies have identified additional genetic modifiers that specifically influence onset age. A single nucleotide polymorphism (SNP) rs7577851 within the AAK1 gene has been linked to an estimated 6.9-year earlier onset of PD. [1] The AAK1 gene operates within the same biological pathway as GAK, another gene influencing PD risk, underscoring how genes along shared pathways can collectively modify disease pathology and onset. [1] Furthermore, an intronic SNP, rs10918270, in the ATF6 gene, showed a strong association with an average 2.3-year younger onset of PD, highlighting the diverse genetic landscape impacting this trait. [1]
Cellular Stress Responses and Protein Homeostasis
The precise timing of disease onset is intimately linked to the cellular mechanisms that maintain protein quality control and overall cellular health. The ATF6 gene, implicated in PD onset age, encodes a crucial transcription factor located in the endoplasmic reticulum (ER). [1] This protein is a critical regulator of the Unfolded Protein Response (UPR), a conserved cellular pathway activated when misfolded proteins accumulate in the ER. [1] An efficient UPR is vital for restoring protein homeostasis, and dysregulation can lead to chronic ER stress, contributing to neuronal dysfunction and potentially accelerating the onset of neurodegenerative conditions like PD.
The functional relationship between the AAK1 and GAK genes further points to the importance of lysosomal activity in PD etiology and onset. [1] Lysosomes are cellular organelles responsible for the degradation and recycling of cellular waste, including misfolded proteins and damaged components. Impairments in lysosomal pathways can result in the accumulation of toxic cellular debris, which can trigger neurodegeneration and influence the age at which PD symptoms first become noticeable. [1] These findings emphasize that robust cellular metabolic processes and regulatory networks are fundamental in protecting neurons and delaying the manifestation of disease.
Neuromelanin and Pigmentation Pathways
Beyond the core mechanisms of protein handling, less-explored biological pathways, such as those related to pigmentation, also appear to modify the age of PD onset. The gene OCA2, known for its role in oculocutaneous albinism, contains a SNP (rs17565841) associated with an average 2.8 to 3.3 years younger PD onset. [1] OCA2 is involved in regulating melanosomal pH, a process critical for the synthesis of melanin, including neuromelanin. [1] Neuromelanin is a distinct pigment found in the dopaminergic neurons of the substantia nigra, the brain region primarily affected in PD, suggesting a potential link between neuromelanin metabolism, neuronal vulnerability, and the timing of disease onset.
An intronic SNP in the DSG3 gene (rs1941184) also showed an association with an average 2.3 years younger age of onset. [1] While DSG3 is predominantly expressed in the skin, some studies indicate increased expression of its encoded protein in melanocytes. [1] This connection further supports the hypothesis that biological mechanisms related to melanin synthesis and regulation, potentially involving neuromelanin in the brain, may play a role in modifying the age at which PD symptoms begin. These insights broaden the understanding of the diverse biological factors that influence disease penetrance and expression.
Systemic and Developmental Influences
The age at which Parkinson's disease symptoms manifest is profoundly influenced by broader systemic factors and the cumulative impact of aging on biological systems. Age itself is a prominent risk factor for PD, indicating that age-related penetrance is strongly associated with how the disease expresses itself. [1] This suggests that the brain's capacity for maintaining homeostasis and enacting compensatory responses gradually declines over time, rendering it more susceptible to the pathological changes that eventually trigger the onset of symptoms. Identifying genetic modifiers of onset age offers crucial insights into these age-related mechanisms that modify disease penetrance, providing valuable targets for interventions aimed at delaying disease. [1]
Genes like MCTP2, expressed in the brain, have been implicated in other conditions, suggesting a complex interplay of genetic factors that may broadly affect neurological health and indirectly influence PD onset. [1] Furthermore, regions near SORCS3 on chromosome 10q have been linked to an older onset age, illustrating that various genetic factors can have differing effects on the timing of disease manifestation. [1] Studying onset age provides a fundamental understanding of the disease process, moving beyond simple susceptibility to unraveling the intricate combination of genetic, cellular, and systemic factors that dictate the progression and ultimate expression of PD symptoms.
Genetic Modifiers and Disease Trajectory
The age at onset in Parkinson disease (PD) is a highly heritable trait, and identifying its genetic modifiers offers significant clinical utility. Genetic studies, such as the first genomewide association study (GWAS) for onset age in PD, have begun to uncover specific genetic variants that influence when symptoms appear [1] For instance, variants in genes like _AAK1_, _OCA2_, _DSG3_, and _ATF6_ have been associated with earlier onset of PD, suggesting their role in accelerating disease progression [1] Understanding these genetic influences provides fundamental insight into the pathogenic mechanisms of PD and is crucial for developing therapeutic targets capable of delaying symptom onset, thereby reducing the overall burden of the disease in an aging population [1]
Risk Assessment and Personalized Therapeutic Strategies
Genetic associations with age at onset can be instrumental in enhancing risk stratification and guiding personalized medicine approaches for PD patients. The identification of specific single nucleotide polymorphisms (SNPs) associated with a younger onset, such as *rs7577851* in _AAK1_ correlating with an estimated 6.9-year earlier onset, or *rs17565841* near _OCA2_ with a 2.8 to 3.3-year earlier onset, can help identify individuals at higher risk for early disease manifestation [1] This knowledge could enable clinicians to implement earlier monitoring strategies, tailor preventive interventions, or select specific treatments designed to modify disease progression based on an individual's unique genetic profile. Distinguishing these age-at-onset modifying genes from genes that merely influence disease susceptibility is vital for developing targeted and effective therapeutic strategies [1]
Pathway Insights and Associated Conditions
Investigating the genetic basis of age at onset provides a deeper understanding of the complex biological pathways involved in PD etiology, potentially revealing connections to other conditions. The gene _AAK1_, for example, is in the same pathway as _GAK_, a previously identified susceptibility-associated gene, suggesting that genes within shared pathways can modify disease pathology in different ways, influencing both onset and progression [1] Furthermore, the identification of candidate regions, such as one containing _MCTP2_, which is expressed in the brain and implicated in conditions like abdominal fat accumulation and major depression, highlights potential overlapping genetic influences or shared biological mechanisms between PD and certain comorbidities [1] Exploring these broader associations can lead to a more comprehensive understanding of PD and its related health issues, fostering more holistic patient care.
Genetic Epidemiology of Age at Onset
Population studies employing genome-wide association studies (GWAS) have been instrumental in identifying genetic factors influencing the age at which various conditions manifest. The first GWAS specifically investigating age at onset in Parkinson disease (PD) analyzed data from 857 familial PD cases, followed by a second GWAS on 440 randomly ascertained PD cases, which were then combined in a meta-analysis of approximately 2 million single nucleotide polymorphisms (SNPs). [1] This comprehensive approach aimed to pinpoint genetic modifiers that could serve as therapeutic targets to delay disease onset, thereby reducing prevalence and easing the burden on aging populations. [1] While no SNPs reached the conventional genome-wide significance threshold, suggestive associations were found, such as rs7577851 within the AAK1 gene, associated with an estimated 6.9 years earlier onset, and rs17565841 near OCA2, linked to approximately 2.8 to 3.3 years younger onset depending on the genetic model. [1]
Beyond neurodegenerative disorders, large-scale meta-analyses of GWAS have also uncovered numerous genetic loci associated with the timing of other significant life events and health conditions. For instance, a meta-analysis identified thirty new loci for age at menarche, highlighting the complex genetic architecture underlying pubertal timing across diverse populations. [11] Similarly, studies have explored the genetic correlates of age at onset for conditions like bipolar disorder, defining onset as the year of the earliest episode of depression or mania, and early-onset extreme obesity, which identified novel loci through joint analyses of French and German cohorts. [6] These broad investigations demonstrate the power of large cohort studies and meta-analytical approaches to uncover genetic influences on the timing of disease and developmental milestones.
Cross-Population and Demographic Patterns in Onset Age
The age at onset for various conditions often exhibits variations across different populations and demographic groups, influenced by a combination of genetic backgrounds and environmental factors. In the Parkinson disease onset age GWAS, a replication study involving an independent sample of 747 PD cases from Milan, Italy, was conducted to validate initial findings. [1] Although differences in age distributions were observed across the studied populations, the Milan cohort showed modest statistical association with consistent directions of effect for key SNPs, underscoring the importance of cross-population validation in genetic research. [1]
Further insights into population-specific effects and broader epidemiological trends emerge from studies involving diverse international collaborations. The meta-analysis for age at menarche, for example, involved numerous research institutions across Europe, North America, and Australia, suggesting a wide demographic and geographic representation that allows for the examination of ancestry and regional variations. [11] Longitudinal cohort studies, such as the Framingham Heart Study, provide critical data on age-related phenotypes like age at death, continuously monitoring participants and employing detailed strategies for event ascertainment. [4] These studies meticulously adjust for demographic factors, including birth cohort, education, and various health indicators, to understand how these elements correlate with the timing of health outcomes and mortality patterns within a population. [4]
Methodological Approaches and Challenges in Onset Age Studies
Investigating age at onset requires robust methodological approaches to ensure the reliability and generalizability of findings. A crucial aspect involves the precise ascertainment of onset age, which for Parkinson disease, was determined through patient interviews reflecting the age of the first symptom, a method with high estimated reliability compared to medical records. [1] To enhance the power of meta-analyses and facilitate joint analysis across different datasets, imputation of nearly 2 million SNPs using HapMap data is commonly employed, allowing for a more comprehensive genomic coverage. [1] Statistical analyses often consider additive, dominant, and recessive modes of inheritance to capture diverse genetic effects on onset age. [1]
Despite these advanced methodologies, studies on age at onset face several challenges and limitations. Ensuring sample representativeness is paramount; for instance, some studies explicitly exclude samples with limited variability in age at onset distribution to avoid skewed results. [1] Population stratification, where differences in allele frequencies between subgroups could lead to spurious associations, is typically addressed using principal components analysis to correct for underlying ancestral variations. [1] Furthermore, while GWAS provide an unprecedented opportunity to identify genetic modifiers, achieving the stringent genome-wide significance threshold remains a considerable hurdle, especially when testing multiple genetic models, which can impact the overall type I error rate. [1]
Frequently Asked Questions About Age At Onset
These questions address the most important and specific aspects of age at onset based on current genetic research.
1. My dad got Parkinson's disease young; does that mean my symptoms will start early too?
Not necessarily at the exact same age, but genetic factors are highly heritable and play a significant role in determining when symptoms first appear. These genetic influences act as "modifiers," shifting onset earlier or later, independent of whether you get the disease. For instance, specific genetic markers near genes like OCA2 have been linked to younger Parkinson's onset.
2. Can my diet or exercise habits actually change when a disease might start for me?
Yes, they can. While genetics play a big part, age at onset is also influenced by a complex interplay of genetic and environmental factors. Your lifestyle choices, including diet and exercise, are environmental factors that can interact with your genetic predispositions to potentially influence the timing of symptom manifestation.
3. If I have a genetic risk for a condition, is my disease onset time set in stone?
No, it's not entirely set in stone. Although genetic factors are highly influential, they often act as "modifiers" that can shift the onset earlier or later, rather than fixing it to a precise age. Environmental factors and other lifestyle choices can also play a role in this variability.
4. Could a new medicine or therapy really stop my symptoms from starting earlier?
Potentially, yes. Identifying the genes and genetic variants that influence age at onset is crucial because they represent valuable therapeutic targets. By understanding the biological mechanisms that accelerate or delay disease onset, researchers aim to develop interventions specifically designed to postpone the manifestation of symptoms.
5. My sibling got sick much later than I did with the same condition; how is that possible?
Even with shared family genetics, there can be significant variability in age at onset between siblings due to a complex interplay of genetic modifiers and environmental factors. Different combinations of these influences can lead to distinct timings for when symptoms first appear in individuals.
6. Does my family's ethnic background affect when a disease might typically show up for me?
Yes, it can. Genetic influences on age at onset can vary across different ancestral groups. Many studies are primarily conducted in populations of European descent, meaning that genetic factors or architectures specific to other populations might be different or not yet fully understood.
7. If I get a genetic test, can it tell me exactly when my disease will begin?
A genetic test can provide valuable insights into your predisposition and potential timing, aiding in prognosis and personalized management. However, predicting an exact age is challenging because age at onset is influenced by many genetic modifiers and environmental factors, not just one single genetic marker.
8. Why is it so important to understand disease onset now, especially with more people living longer?
In an aging global population, chronic and neurodegenerative diseases are becoming more common. Understanding and delaying disease onset, even by a few years, can significantly improve the quality of life for millions, reduce disease prevalence, and alleviate the burden on healthcare systems and families.
9. Does being generally healthy, like avoiding smoking, really delay when my symptoms start?
Yes, maintaining a generally healthy lifestyle can be beneficial. Environmental factors, including lifestyle choices such as smoking or other medical conditions, can interact with your genetic predispositions. Accounting for these factors is crucial, as they can influence the timing of symptom onset.
10. If I have a strong family history, will my children automatically get the disease at the same age I did?
Not necessarily at the exact same age. While genetic factors influencing age at onset are often highly heritable, the specific timing can vary. This is because a complex interplay of many genetic modifiers and environmental factors contributes to when symptoms appear, making it unlikely to be an identical timeline for every family member.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Latourelle, J. C. et al. "Genomewide association study for onset age in Parkinson disease." BMC Med Genet, 2009.
[2] He, Chunyu, et al. "Genome-wide association studies identify loci associated with age at menarche and age at natural menopause." Nature Genetics, 2009.
[3] Siedlinski, Mateusz, et al. "Genome-wide association study of smoking behaviours in patients with COPD." Thorax, 2011.
[4] Lunetta, K. L. et al. "Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study." BMC Med Genet, 2007.
[5] Kamboh, M. Ilyas, et al. "Genome-wide association analysis of age-at-onset in Alzheimer's disease." Molecular Psychiatry, 2011.
[6] Belmonte Mahon, P. et al. "Genome-wide association analysis of age at onset and psychotic symptoms in bipolar disorder." Am J Med Genet B Neuropsychiatr Genet, 2011.
[7] Scherag, A. et al. "Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups." PLoS Genet, 2010.
[8] Ong, K. K., et al. "Genetic variation in LIN28B is associated with the timing of puberty." Nat Genet, vol. 41, no. 6, 2009, pp. 729-733.
[9] Lasky-Su, J., et al. "Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder." Am J Med Genet B Neuropsychiatr Genet, vol. 147B, no. 8, 2008, pp. 1355-1358.
[10] Yang, H. C., et al. "Genome-wide association study of young-onset hypertension in the Han Chinese population of Taiwan." PLoS One, vol. 4, no. 5, 2009, e5551.
[11] Elks, C. E. et al. "Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies." Nat Genet, 2010.